AB-201

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameAB-201

Drug Alias NameHER2 CAR-NK Cell Therapy (Artiva Biotherapeutics)GCC2003AB-201 (Artiva Biotherapeutics)GCC-2003

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionAnti-HER2

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaSouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGC Cell Corp

China Registration ClassN/A

Develop Information

Active CompaniesYonsei University GC Cell Corp Artiva Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursStomach NeoplasmsNeoplasms

Inactive IndicationsGastroesophageal Junction NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A